Floatz logo

Gemtuzumab Ozogamicin

Acute Myeloid Leukemia, Myelodysplasia-Related

National Cancer Institute (NCI)antibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

35 Active assets in the Acute Myeloid Leukemia, Myelodysplasia-Related cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BB
ETOPOSIDE
Institut de Recherches Internationales Servier
Phase 2BB
Daunorubicin
Institut de Recherches Internationales Servier
Phase 3BB
Decitabine
National Cancer Institute (NCI)
Phase 3BB
ag-120
Institut de Recherches Internationales Servier
Phase 3BB

View all 50 →

Same molecule, other indications

Gemtuzumab Ozogamicin is also rated in:

leukemiaDormant
BB
Indicative ·
69 / 100
View asset →
acute myeloid leukemiaDormant
BB
Indicative ·
67 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →